BHCM
AGIO icon

Brevan Howard Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Brevan Howard Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
9,290
-15,179
-62% -$460K ﹤0.01% 1625
2026
Q1 		$867K Buy
24,469
+5,133
+27% +$146K 0.01% 984
2025
Q4 		$526K Buy
19,336
+7,265
+60% +$255K 0.01% 1086
2025
Q3 		$485K Sell
12,071
-17,106
-59% -$643K ﹤0.01% 1304
2025
Q2 		$970K Buy
+29,177
New +$884K 0.01% 1075
2025
Q1 		– Sell
-47,326
Closed -$1.56M – 1131
2024
Q4 		$1.56M Buy
47,326
+36,599
+341% +$1.72M 0.01% 330
2024
Q3 		$477K Sell
10,727
-3,102
-22% -$141K ﹤0.01% 693
2024
Q2 		$596K Sell
13,829
-2,507
-15% -$90.5K 0.01% 547
2024
Q1 		$478K Sell
16,336
-2,208
-12% -$59.1K ﹤0.01% 481
2023
Q4 		$413K Buy
+18,544
New +$416K 0.01% 569

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Brevan Howard Capital Management's AGIO Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Agios Pharmaceuticals (AGIO) stake by 62% in Q2 2026, selling an estimated $460K and leaving 9,290 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1625.

Brevan Howard Capital Management first reported a position in AGIO in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.56M in Q4 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Brevan Howard Capital Management held 9,290 shares of Agios Pharmaceuticals worth $345K as of Q2 2026.
  • Brevan Howard Capital Management sold 15,179 Agios Pharmaceuticals shares in Q2 2026, an estimated $460K.
  • Agios Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1625 holding.
  • Brevan Howard Capital Management first reported a position in Agios Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Brevan Howard Capital Management's Agios Pharmaceuticals position peaked at $1.56M in Q4 2024.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.